Michigan Senate candidate El-Sayed rebuts RFK Jr. and highlights FDA's new enforcement discretion on peptide drugs

Abdul El-Sayed, the Democratic Senate hopeful in Michigan, pushed back against recent statements made by RFK Jr., defending his own health-care positions and emphasizing his background as an immigrant-descended health-equity researcher.

In the same newsletter, the FDA announced a shift in how it will handle peptide-based medicines, opting for a more flexible enforcement approach that could affect how companies develop and market these products.

The policy change signals a potential easing of regulatory pressure for peptide drug developers, which may influence investment decisions and the pace of innovation in that therapeutic area.

Both the political clash and the regulatory update underscore the ongoing intersection of health policy and pharmaceutical regulation in Washington.